11 results on '"Huscher, Dörte"'
Search Results
2. Mobile App-based documentation of patient-reported outcomes — 3-months results from a proof-of-concept study on modern rheumatology patient management
- Author
-
Richter, Jutta G., Nannen, Christina, Chehab, Gamal, Acar, Hasan, Becker, Arnd, Willers, Reinhart, Huscher, Dörte, and Schneider, Matthias
- Published
- 2021
- Full Text
- View/download PDF
3. Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study
- Author
-
Mielke, Nina, Huscher, Dörte, Douros, Antonios, Ebert, Natalie, Gaedeke, Jens, van der Giet, Markus, Kuhlmann, Martin K., Martus, Peter, and Schaeffner, Elke
- Published
- 2020
- Full Text
- View/download PDF
4. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
- Author
-
Blagojevic, Jelena, Bellando-Randone, Silvia, Abignano, Giuseppina, Avouac, Jérôme; https://orcid.org/0000-0002-2463-218X, Cometi, L, Czirják, László, Denton, Christopher P; https://orcid.org/0000-0003-3975-8938, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Frerix, Marc, Guiducci, Serena, Huscher, Dörte, Jaeger, Veronika K, Lóránd, Veronika, Maurer, Britta; https://orcid.org/0000-0001-9385-8097, Nihtyanova, Svetlana, Riemekasten, Gabriela, Siegert, Elise; https://orcid.org/0000-0002-9594-0446, Tarner, Ingo H, Vettori, Serena, Walker, Ulrich A; https://orcid.org/0000-0002-9183-550X, Allanore, Yannick; https://orcid.org/0000-0002-6149-0002, Müller-Ladner, Ulf, Del Galdo, Francesco; https://orcid.org/0000-0002-8528-2283, Matucci-Cerinic, Marco; https://orcid.org/0000-0002-9324-3161, EUSTAR co-workers, Blagojevic, Jelena, Bellando-Randone, Silvia, Abignano, Giuseppina, Avouac, Jérôme; https://orcid.org/0000-0002-2463-218X, Cometi, L, Czirják, László, Denton, Christopher P; https://orcid.org/0000-0003-3975-8938, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Frerix, Marc, Guiducci, Serena, Huscher, Dörte, Jaeger, Veronika K, Lóránd, Veronika, Maurer, Britta; https://orcid.org/0000-0001-9385-8097, Nihtyanova, Svetlana, Riemekasten, Gabriela, Siegert, Elise; https://orcid.org/0000-0002-9594-0446, Tarner, Ingo H, Vettori, Serena, Walker, Ulrich A; https://orcid.org/0000-0002-9183-550X, Allanore, Yannick; https://orcid.org/0000-0002-6149-0002, Müller-Ladner, Ulf, Del Galdo, Francesco; https://orcid.org/0000-0002-8528-2283, Matucci-Cerinic, Marco; https://orcid.org/0000-0002-9324-3161, and EUSTAR co-workers
- Abstract
BACKGROUND A consensus on digital ulcer (DU) definition in systemic sclerosis (SSc) has been recently reached (Suliman et al., J Scleroderma Relat Disord 2:115-20, 2017), while for their evaluation, classification and categorisation, it is still missing. The aims of this study were to identify a set of essential items for digital ulcer (DU) evaluation, to assess if the existing DU classification was useful and feasible in clinical practice and to investigate if the new categorisation was preferred to the simple distinction of DU in recurrent and not recurrent, in patients with systemic sclerosis (SSc). METHODS DeSScipher is the largest European multicentre study on SSc. It consists of five observational trials (OTs), and one of them, OT1, is focused on DU management. The DeSScipher OT1 items on DU that reached ≥ 60% of completion rate were administered to EUSTAR (European Scleroderma Trials and Research group) centres via online survey. Questions about feasibility and usefulness of the existing DU classification (DU due to digital pitting scars, to loss of tissue, derived from calcinosis and gangrene) and newly proposed categorisation (episodic, recurrent and chronic) were also asked. RESULTS A total of 84/148 (56.8%) EUSTAR centres completed the questionnaire. DeSScipher items scored by ≥ 70% of the participants as essential and feasible for DU evaluation were the number of DU defined as a loss of tissue (level of agreement 92%), recurrent DU (84%) and number of new DU (74%). For 65% of the centres, the proposed classification of DU was considered useful and feasible in clinical practice. Moreover, 80% of the centres preferred the categorisation of DU in episodic, recurrent and chronic to simple distinction in recurrent/not recurrent DU. CONCLUSIONS For clinical practice, EUSTAR centres identified only three essential items for DU evaluation and considered the proposed classification and categorisation as useful and feasible. The set of items needs to be validated
- Published
- 2019
5. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
- Author
-
Adler, Sabine, Huscher, Dörte, Siegert, Elise; https://orcid.org/0000-0002-9594-0446, Allanore, Yannick; https://orcid.org/0000-0002-6149-0002, Czirják, László, DelGaldo, Francesco, Denton, Christopher P; https://orcid.org/0000-0003-3975-8938, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Frerix, Marc, Matucci-Cerinic, Marco; https://orcid.org/0000-0002-9324-3161, Mueller-Ladner, Ulf, Tarner, Ingo-Helmut, Valentini, Gabriele, Walker, Ulrich A; https://orcid.org/0000-0002-9183-550X, Villiger, Peter M, Riemekasten, Gabriela, Adler, Sabine, Huscher, Dörte, Siegert, Elise; https://orcid.org/0000-0002-9594-0446, Allanore, Yannick; https://orcid.org/0000-0002-6149-0002, Czirják, László, DelGaldo, Francesco, Denton, Christopher P; https://orcid.org/0000-0003-3975-8938, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Frerix, Marc, Matucci-Cerinic, Marco; https://orcid.org/0000-0002-9324-3161, Mueller-Ladner, Ulf, Tarner, Ingo-Helmut, Valentini, Gabriele, Walker, Ulrich A; https://orcid.org/0000-0002-9183-550X, Villiger, Peter M, and Riemekasten, Gabriela
- Abstract
BACKGROUND: Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-related death. Imunosuppressive treatment (IS) is used in patients with SSc for various organ manifestations mainly to ameliorate progression of SSc-ILD. Data on everyday IS prescription patterns and clinical courses of lung function during and after therapy are scarce. METHODS: We analysed patients fulfilling American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2013 criteria for SSc-ILD and at least one report of IS. Types of IS, pulmonary function tests (PFT) and PFT courses during IS treatment were evaluated. RESULTS: EUSTAR contains 3778/11,496 patients with SSc-ILD (33%), with IS in 2681/3,778 (71%). Glucocorticoid (GC) monotherapy was prescribed in 30.6% patients with GC combinations plus cyclophosphamide (CYC) (11.9%), azathioprine (AZA) (9.2%), methotrexate (MTX) (8.7%), or mycophenolate mofetil (MMF) (7.3%). Intensive IS (MMF + GC, CYC or CYC + GC) was started in patients with the worst PFTs and ground glass opacifications on imaging. Patients without IS showed slightly less worsening in forced vital capacity (FVC) when starting with FVC 50-75% or >75%. GC showed negative trends when starting with FVC <50%. Regarding diffusing capacity for carbon monoxide (DLCO), negative DLCO trends were found in patients with MMF. CONCLUSIONS: IS is broadly prescribed in SSc-ILD. Clusters of clinical and functional characteristics guide individualised treatment. Data favour distinguished decision-making, pointing to either watchful waiting and close monitoring in the early stages or start of immunosuppressive treatment in moderately impaired lung function. Advantages of specific IS are difficult to depict due to confounding by indication. Data do not support liberal use of GC in SSc-ILD.
- Published
- 2018
6. Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases.
- Author
-
Albrecht, Katinka, Richter, Adrian, Callhoff, Johanna, Huscher, Dörte, Schett, Georg, Strangfeld, Anja, and Zink, Angela
- Published
- 2016
- Full Text
- View/download PDF
7. Acute murine antigen-induced arthritis is not affected by disruption of osteoblastic glucocorticoid signalling.
- Author
-
Spies, Cornelia M., Wiebe, Edgar, Jinwen Tu, Aiqing Li, Gaber, Timo, Huscher, Dörte, Seibel, Markus J., Hong Zhou, and Buttgereit, Frank
- Subjects
RHEUMATOID arthritis ,GLUCOCORTICOIDS ,OSTEOBLASTS ,HYDROXYSTEROID dehydrogenases ,ANIMAL disease models ,T cells - Abstract
Background The role of endogenous glucocorticoids (GC) in the initiation and maintenance of rheumatoid arthritis (RA) remains unclear. We demonstrated previously that disruption of GC signalling in osteoblasts results in a profound attenuation of K/BxN serum-induced arthritis, a mouse model of RA. To determine whether or not the modulation of the inflammatory response by osteoblasts involves T cells, we studied the effects of disrupted osteoblastic GC-signalling in the T cell-dependent model of antigen-induced arthritis (AIA). Methods Acute arthritis was induced in pre-immunised 11-week-old male 11ß-hydroxysteroid dehydrogenase type 2 transgenic (tg) mice and their wild-type (WT) littermates by intraarticular injection of methylated bovine serum albumine (mBSA) into one knee joint. Knee diameter was measured every 1–2 days until euthanasia on day 14 post injection. In a separate experiment, arthritis was maintained for 28 days by weekly reinjections of mBSA. Tissues were analysed by histology, histomorphometry and microfocal-computed tomography. Serum cytokines levels were determined by multiplex suspension array. Results In both short and long term experiments, arthritis developed in tg and WT mice with no significant difference between both groups. Histological indices of inflammation, cartilage damage and bone erosion were similar in tg and WT mice. Bone volume and turnover at the contralateral tibia and systemic cytokine levels were not different. Conclusions Acute murine AIA is not affected by a disruption in osteoblastic GC signalling. These data indicate that osteoblasts do not modulate the T cell-mediated inflammatory response via a GC-dependent pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
8. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
- Author
-
Adler, Sabine, Huscher, Dörte, Siegert, Elise, Allanore, Yannick, Czirják, László, DelGaldo, Francesco, Denton, Christopher P, Distler, Oliver, Frerix, Marc, Matucci-Cerinic, Marco, Mueller-Ladner, Ulf, Tarner, Ingo-Helmut, Valentini, Gabriele, Walker, Ulrich A, Villiger, Peter, and Riemekasten, Gabriela
- Subjects
respiratory system ,skin and connective tissue diseases ,610 Medicine & health ,respiratory tract diseases ,3. Good health - Abstract
BACKGROUND Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-related death. Imunosuppressive treatment (IS) is used in patients with SSc for various organ manifestations mainly to ameliorate progression of SSc-ILD. Data on everyday IS prescription patterns and clinical courses of lung function during and after therapy are scarce. METHODS We analysed patients fulfilling American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2013 criteria for SSc-ILD and at least one report of IS. Types of IS, pulmonary function tests (PFT) and PFT courses during IS treatment were evaluated. RESULTS EUSTAR contains 3778/11,496 patients with SSc-ILD (33%), with IS in 2681/3,778 (71%). Glucocorticoid (GC) monotherapy was prescribed in 30.6% patients with GC combinations plus cyclophosphamide (CYC) (11.9%), azathioprine (AZA) (9.2%), methotrexate (MTX) (8.7%), or mycophenolate mofetil (MMF) (7.3%). Intensive IS (MMF + GC, CYC or CYC + GC) was started in patients with the worst PFTs and ground glass opacifications on imaging. Patients without IS showed slightly less worsening in forced vital capacity (FVC) when starting with FVC 50-75% or >75%. GC showed negative trends when starting with FVC
9. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
- Author
-
Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, and Riemekasten G
- Subjects
- Adult, Aged, Cyclophosphamide therapeutic use, Drug Therapy, Combination, Female, Humans, Lung pathology, Lung physiopathology, Lung Diseases, Interstitial complications, Lung Diseases, Interstitial physiopathology, Male, Methotrexate therapeutic use, Middle Aged, Mycophenolic Acid therapeutic use, Precision Medicine methods, Respiratory Function Tests, Scleroderma, Systemic complications, Immunosuppressive Agents therapeutic use, Lung drug effects, Lung Diseases, Interstitial drug therapy, Scleroderma, Systemic drug therapy
- Abstract
Background: Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-related death. Imunosuppressive treatment (IS) is used in patients with SSc for various organ manifestations mainly to ameliorate progression of SSc-ILD. Data on everyday IS prescription patterns and clinical courses of lung function during and after therapy are scarce., Methods: We analysed patients fulfilling American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) 2013 criteria for SSc-ILD and at least one report of IS. Types of IS, pulmonary function tests (PFT) and PFT courses during IS treatment were evaluated., Results: EUSTAR contains 3778/11,496 patients with SSc-ILD (33%), with IS in 2681/3,778 (71%). Glucocorticoid (GC) monotherapy was prescribed in 30.6% patients with GC combinations plus cyclophosphamide (CYC) (11.9%), azathioprine (AZA) (9.2%), methotrexate (MTX) (8.7%), or mycophenolate mofetil (MMF) (7.3%). Intensive IS (MMF + GC, CYC or CYC + GC) was started in patients with the worst PFTs and ground glass opacifications on imaging. Patients without IS showed slightly less worsening in forced vital capacity (FVC) when starting with FVC 50-75% or >75%. GC showed negative trends when starting with FVC <50%. Regarding diffusing capacity for carbon monoxide (DLCO), negative DLCO trends were found in patients with MMF., Conclusions: IS is broadly prescribed in SSc-ILD. Clusters of clinical and functional characteristics guide individualised treatment. Data favour distinguished decision-making, pointing to either watchful waiting and close monitoring in the early stages or start of immunosuppressive treatment in moderately impaired lung function. Advantages of specific IS are difficult to depict due to confounding by indication. Data do not support liberal use of GC in SSc-ILD.
- Published
- 2018
- Full Text
- View/download PDF
10. Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort.
- Author
-
Hanke K, Dähnrich C, Brückner CS, Huscher D, Becker M, Jansen A, Meyer W, Egerer K, Hiepe F, Burmester GR, Schlumberger W, and Riemekasten G
- Subjects
- Autoantigens immunology, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoblotting, Male, Middle Aged, Prognosis, Scleroderma, Systemic pathology, Sensitivity and Specificity, Autoantibodies blood, Biomarkers blood, DNA Topoisomerases, Type I immunology, Scleroderma, Systemic blood, Scleroderma, Systemic diagnosis
- Abstract
Introduction: In the present study, the detection of anti-topoisomerase I (anti-topo I) autoantibodies was evaluated for diagnosis and risk assessment of systemic sclerosis (SSc) patients in a well characterized large monocentric cohort., Methods: Sera from patients with SSc (diffuse n = 96, limited n = 113), from patients with overlap syndromes (n = 51), from patients with other diseases associated with SSc (n = 20), as well as from disease controls (n = 487) were analysed for the presence of anti-topo I antibodies by line immunoblot assay and ELISA. Assessment of organ manifestations was performed as proposed by the European Scleroderma Trial and Research network., Results: The applied test systems for the detection of anti-topo I antibodies revealed a diagnostic sensitivity for SSc of approximately 24% and a diagnostic specificity of at least 99.6%. The sensitivity to identify patients with diffuse SSc amounted to 60%. Patients with anti-topo I antibodies showed a higher burden of skin and lung fibrosis, contractures, electrocardiogram changes, as well as digital ulcers and had more active disease than antibody-negative patients. Signal strengths correlated only weakly with disease activity, with modified Rodnan skin score, with predicted forced vital capacity, and with predicted diffusion capacity levels (P = 0.01, rho = 0.234, rho = 0.413, rho = -0.215, rho = -0.219). High signal intensities were associated with an increased mortality in diffuse SSc patients (P = 0.003)., Conclusions: Diagnosis and risk assessment of SSc patients can be supported by the detection of anti-topo I antibodies. Signal intensities as obtained by line immunoblot assay or ELISA can be used as a surrogate marker for fibrosis, active disease and worse prognosis.
- Published
- 2009
- Full Text
- View/download PDF
11. Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.
- Author
-
Hanke K, Brückner CS, Dähnrich C, Huscher D, Komorowski L, Meyer W, Janssen A, Backhaus M, Becker M, Kill A, Egerer K, Burmester GR, Hiepe F, Schlumberger W, and Riemekasten G
- Subjects
- Exoribonucleases, Exosome Multienzyme Ribonuclease Complex, Humans, Immunoblotting, Middle Aged, Scleroderma, Systemic physiopathology, Sensitivity and Specificity, Autoantibodies blood, Autoantibodies immunology, Autoantigens immunology, Biomarkers blood, Scleroderma, Systemic blood, Scleroderma, Systemic immunology
- Abstract
Introduction: Anti-PM/Scl antibodies are present in sera from patients with polymyositis (PM), systemic sclerosis (SSc), and PM/SSc overlap syndromes. The prevalence of antibodies against the 75- and 100-kDa PM/Scl proteins and their clinical associations have not been studied in SSc patients in detail so far but could provide a valuable tool for risk assessment in these patients. Furthermore, it remains speculative whether commercially available test systems detecting only anti-PM/Scl-100 antibodies are sufficient in SSc patients., Methods: Two hundred eighty sera from SSc patients, patients with other connective tissue diseases (n = 209), and healthy blood donors (n = 50) were analyzed for the presence of anti-PM/Scl-75 and anti-PM/Scl-100 antibodies by means of line immunoblot assay. For the SSc patients, possible associations between both subsets of anti-PM/Scl antibodies with clinical and laboratory findings were studied., Results: The determination of anti-PM/Scl reactivity revealed a diagnostic sensitivity of 12.5% and a specificity of 96.9% for SSc. Among anti-PM/Scl-positive SSc patients, 10.4% and 7.1% were positive for anti-PM/Scl-75 and anti-PM/Scl-100 antibodies, respectively. The highest prevalences of reactivity to PM/Scl were detected in diffuse SSc (19.8%) and overlap syndromes (17.6%). Patients with diffuse SSc showed mainly an anti-PM/Scl-75 response, whereas most cases of overlap syndromes were characterized by reactivity to both PM/Scl antigens. The presence of anti-PM/Scl-75/100 antibodies was associated with muscular and lung involvements as well as with digital ulcers; pulmonary arterial hypertension was found less frequently. Anti-PM/Scl-75 antibodies were detected more frequently in younger and more active patients with joint contractures. Anti-PM/Scl-100 antibodies were associated with creatine kinase elevation; however, gastrointestinal involvements were observed less frequently., Conclusions: Anti-PM/Scl antibodies are common in distinct SSc subsets and are associated with several clinical symptoms. They are directed mainly to the PM/Scl-75 antigen. Consequently, the detection of anti-PM/Scl antibodies by tests based only on PM/Scl-100 as an antigen source may miss a relevant number of SSc patients positive for these antibodies.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.